Linked Data API

Show Search Form

Search Results

1700671
registered interest false more like this
date less than 2024-04-15more like thismore than 2024-04-15
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs: Shortages more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government what steps they are taking to mitigate the current shortage of the psychotropic medication Olanzapine, Risperidone and Haloperidol following the sudden departure of two generic manufacturers from the UK market. more like this
tabling member printed
Lord Carlile of Berriew more like this
uin HL3729 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2024-04-22more like thismore than 2024-04-22
answer text <p>We are aware that there have been supply constraints with olanzapine 210 milligram, 300 milligram, and 405 milligram powder and solvent for prolonged release suspension for injection. We worked with manufacturers to uplift production, and the issues were resolved in February 2024. We worked with NHS England to issue national communications containing advice on how to manage patients whilst there was a disruption to supply. We are not aware of any supply issues affecting oral presentations of olanzapine, or of any supply issues with any risperidone or haloperidol products.</p> more like this
answering member printed Lord Markham more like this
grouped question UIN HL3730 more like this
question first answered
less than 2024-04-22T15:15:21.697Zmore like thismore than 2024-04-22T15:15:21.697Z
answering member
4948
label Biography information for Lord Markham more like this
tabling member
1138
label Biography information for Lord Carlile of Berriew more like this
1700672
registered interest false more like this
date less than 2024-04-15more like thismore than 2024-04-15
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Olanzapine: Shortages more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government what assessment they have made of the impact of the shortage of the psychotropic medication Olanzapine, and what steps they are taking to ensure that such shortages do not affect the health and safety of patients, and wider public safety. more like this
tabling member printed
Lord Carlile of Berriew more like this
uin HL3730 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2024-04-22more like thismore than 2024-04-22
answer text <p>We are aware that there have been supply constraints with olanzapine 210 milligram, 300 milligram, and 405 milligram powder and solvent for prolonged release suspension for injection. We worked with manufacturers to uplift production, and the issues were resolved in February 2024. We worked with NHS England to issue national communications containing advice on how to manage patients whilst there was a disruption to supply. We are not aware of any supply issues affecting oral presentations of olanzapine, or of any supply issues with any risperidone or haloperidol products.</p> more like this
answering member printed Lord Markham more like this
grouped question UIN HL3729 more like this
question first answered
less than 2024-04-22T15:15:21.743Zmore like thismore than 2024-04-22T15:15:21.743Z
answering member
4948
label Biography information for Lord Markham more like this
tabling member
1138
label Biography information for Lord Carlile of Berriew more like this
1681314
registered interest false more like this
date less than 2024-01-10more like thismore than 2024-01-10
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Hospices: Children more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government whether they expect integrated care boards in England to be able to identify how much money they spend on children’s hospices; and, if not, what action they will take. more like this
tabling member printed
Lord Carlile of Berriew more like this
uin HL1402 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2024-01-16more like thismore than 2024-01-16
answer text <p>The Government does not hold information regarding the amount of money each integrated care board (ICB) spends on children’s hospices. There is currently no plan to take any action to ensure that ICBs can identify how much money they spend specifically on children’s hospices.</p><p> </p><p>At a national level, NHS England supports palliative and end of life care for children and young people through the Children and Young People’s hospice grant. The grant provided approximately £17 million in 2021/22, £21 million in 2022/23 and £25 million in 2023/24 directly to children and young people’s hospices. NHS England has confirmed that it will be renewing the grant for 2024/25, once again allocating £25 million grant funding for children’s hospices using the same prevalence-based allocation approach as in 2022/23 and 2023/24. NHS England is reprioritising budgets for 2024/25, in light of the revised assessment of financial position and, whilst it is holding funding aside for the children and young people’s hospice sector, it cannot confirm further details, including the distribution mechanism, until 2024/25 financial planning is concluded.</p><p> </p><p>Additionally, in line with the NHS Long Term Plan commitment, NHSE has provided approximately £8.5 million match-funding to participating ICBs and formerly clinical commissioning groups between 2022/23 and 2023/24 that committed to invest in children and young people’s palliative and end of life care, including hospices, giving a total investment of £17 million for that period.</p>
answering member printed Lord Markham more like this
question first answered
less than 2024-01-16T14:23:36.577Zmore like thismore than 2024-01-16T14:23:36.577Z
answering member
4948
label Biography information for Lord Markham more like this
tabling member
1138
label Biography information for Lord Carlile of Berriew more like this
1459747
registered interest false more like this
date less than 2022-04-22more like thismore than 2022-04-22
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Hospital Wards: Transgender People more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government what is their policy for providing in-patient accommodation for trans women in NHS hospital wards in England; and what steps they are taking to protect trans women in hospital from potential discrimination. more like this
tabling member printed
Lord Carlile of Berriew more like this
uin HL7846 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2022-04-27more like thismore than 2022-04-27
answer text <p>NHS England and NHS Improvement’s current guidance concerning the placement of transgender people in hospital wards states that this should be done in accordance with their presentation, such as the way the person dresses and the pronouns they use. NHS England is reviewing this guidance and the Department will ensure that any revised guidance takes account of relevant equalities legislation.</p> more like this
answering member printed Lord Kamall more like this
question first answered
less than 2022-04-27T16:29:04.097Zmore like thismore than 2022-04-27T16:29:04.097Z
answering member
4909
label Biography information for Lord Kamall more like this
tabling member
1138
label Biography information for Lord Carlile of Berriew more like this
984260
registered interest false more like this
date less than 2018-10-09more like thismore than 2018-10-09
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Buprenorphine more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government what action they are taking (1) to remedy any buprenorphine shortage, and (2) to ensure that in the long term there is consistent and adequate supply of this medication, that it is available across the country and is not subject to unpredictable price fluctuations. more like this
tabling member printed
Lord Carlile of Berriew more like this
uin HL10468 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2018-10-17more like thismore than 2018-10-17
answer text <p>We are aware that there was a short-term supply issue which may have affected the availability in May 2018. This was because one of the main suppliers experienced delays in delivery, resulting in a short term out of stock period. Although supplies continued to remain available from other suppliers, we are aware that some may have struggled to support the increase in demand at short notice. The delivery issues were resolved quickly and the overall supply of buprenorphine tablets improved shortly afterwards.</p><p>Since this period, the Department has remained in regular contact with all United Kingdom licensed suppliers of buprenorphine and has been working closely with them to monitor their supply position. Based on these conversations, we have been assured that the available supplies are sufficient to meet the usual UK requirements for this drug. The Department continues to monitor this very closely to ensure that there is consistent and adequate supply of this medication across the country.</p><p>The Department is aware that since this short-term supply issue, the market price has increased. This increased purchase price is reflected in the reimbursement price paid to pharmacies, to ensure that supplies remain available to patients. The market for buprenorphine has generally been competitive and we expect the supply situation to improve over the coming weeks which is likely to result in an increasingly competitive market.</p><p> </p>
answering member printed Lord O'Shaughnessy more like this
question first answered
less than 2018-10-17T15:25:57.393Zmore like thismore than 2018-10-17T15:25:57.393Z
answering member
4545
label Biography information for Lord O'Shaughnessy more like this
tabling member
1138
label Biography information for Lord Carlile of Berriew more like this
979709
registered interest false more like this
date less than 2018-10-01more like thismore than 2018-10-01
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading NHS: Drugs more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government how many technology appraisals NICE has undertaken for medicines which have successfully passed through the Early Access to Medicines Scheme; and how long it has taken for a NICE recommendation to be reached on each of those appraisals. more like this
tabling member printed
Lord Carlile of Berriew more like this
uin HL10366 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2018-10-15more like thismore than 2018-10-15
answer text <p>To date, the National Institute for Health and Care Excellence (NICE) has published final technology appraisal guidance on 18 drugs with a positive Scientific Opinion through the Early Access to Medicines Scheme. Information on the length of time between receipt of a positive Scientific Opinion and final NICE technology appraisal guidance for each drug is attached due to the size of the data.</p> more like this
answering member printed Lord O'Shaughnessy more like this
question first answered
less than 2018-10-15T10:56:04.57Zmore like thismore than 2018-10-15T10:56:04.57Z
answering member
4545
label Biography information for Lord O'Shaughnessy more like this
attachment
1
file name HL10366 table formatted.docx more like this
title Time between Scientific Opinion and NICE guidance more like this
tabling member
1138
label Biography information for Lord Carlile of Berriew more like this
980121
registered interest false more like this
date less than 2018-10-01more like thismore than 2018-10-01
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Glioblastoma: Drugs more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government whether new biomarker-linked treatments for glioblastoma multiforme would be considered candidate technologies for the Accelerated Access Pathway under the Accelerated Access Review. more like this
tabling member printed
Lord Carlile of Berriew more like this
uin HL10390 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2018-10-15more like thismore than 2018-10-15
answer text <p>As set out in the response to the Accelerated Access Review, the Accelerated Access Pathway (AAP) will focus on affordable products which can dramatically improve efficiency, fill an unmet need or make a step change in patient outcomes.</p><p>There are no restrictions on what type of products the AAP should focus on. The AAP will be launched shortly after the next meeting of the Accelerated Access Collaborative.</p> more like this
answering member printed Lord O'Shaughnessy more like this
question first answered
less than 2018-10-15T11:01:04.617Zmore like thismore than 2018-10-15T11:01:04.617Z
answering member
4545
label Biography information for Lord O'Shaughnessy more like this
tabling member
1138
label Biography information for Lord Carlile of Berriew more like this
980122
registered interest false more like this
date less than 2018-10-01more like thismore than 2018-10-01
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Glioblastoma: Drugs more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government what steps they are taking to support future patient access to new and clinically-effective medicines for glioblastoma multiforme. more like this
tabling member printed
Lord Carlile of Berriew more like this
uin HL10391 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2018-10-15more like thismore than 2018-10-15
answer text <p>A number of drugs currently being developed for potential use in the treatment of glioblastoma have been referred to the National Institute for Health and Care Excellence (NICE) for the development of technology appraisal guidance. New arrangements for the assessment and adoption of cancer drugs were introduced in 2016 that are designed to ensure that patients benefit from rapid access to the most promising new cancer drugs. Under these arrangements, wherever possible, NICE aims to publish draft guidance on cancer drugs before the product receives a marketing authorisation for use in the United Kingdom, and drugs recommended in draft NICE guidance will be eligible for Cancer Drugs Fund funding from the time that the drug receives a marketing authorisation.</p><p>In May, the Government announced £40 million for brain cancer research in honour of Dame Tessa Jowell. Funding will be invested through the National Institute for Health Research to support a wide range of research from early translation (experimental medicine) through clinical and on to applied research. This will support the translation of laboratory discoveries into treatments and better care for patients.</p><p> </p><p> </p>
answering member printed Lord O'Shaughnessy more like this
question first answered
less than 2018-10-15T15:36:13.103Zmore like thismore than 2018-10-15T15:36:13.103Z
answering member
4545
label Biography information for Lord O'Shaughnessy more like this
tabling member
1138
label Biography information for Lord Carlile of Berriew more like this
980123
registered interest false more like this
date less than 2018-10-01more like thismore than 2018-10-01
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading NHS: Drugs more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government what assessment they have made of the implementation of the recommendations of the Independent Review of the Early Access to Medicines Scheme. more like this
tabling member printed
Lord Carlile of Berriew more like this
uin HL10392 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2018-10-15more like thismore than 2018-10-15
answer text <p>Since the publication of the independent review of the Early Access to Medicines Scheme (EAMS) the Government has made a number of improvements.</p><p>Partners have worked together to provide updated guidance on the benefits and entry requirements for EAMS and are developing further guidance on collecting real world data in the scheme to support National Institute for Health and Care Excellence appraisal.</p><p>Furthermore, the EAMS task group exists to provide a forum for industry to engage with Government, the devolved administrations and arm’s length bodies regarding EAMS, as per the recommendations of the 2016 review.</p> more like this
answering member printed Lord O'Shaughnessy more like this
question first answered
less than 2018-10-15T13:52:46.487Zmore like thismore than 2018-10-15T13:52:46.487Z
answering member
4545
label Biography information for Lord O'Shaughnessy more like this
tabling member
1138
label Biography information for Lord Carlile of Berriew more like this
980124
registered interest false more like this
date less than 2018-10-01more like thismore than 2018-10-01
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Buprenorphine more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government what assessment they have made of the availability and price of the opiate treatment medication buprenorphine; whether there is a shortage of buprenorphine; if so, what analysis they have made of the reasons of such a shortage; and whether there are mechanisms in place to monitor the long-term supply of the medication following the recent rise in deaths associated with opioid abuse. more like this
tabling member printed
Lord Carlile of Berriew more like this
uin HL10393 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2018-10-15more like thismore than 2018-10-15
answer text <p>We are aware that there was a short-term supply issue which may have affected availability in May 2018. This was because one of the main generic suppliers experienced delays in delivery, resulting in a short-term out of stock period. Although supplies continued to remain available from other suppliers, we are aware that some may have struggled to support the increase in demand at short notice. The delivery issues were resolved quickly and the overall supply of buprenorphine tablets improved shortly afterwards. The Department has not been made aware of patients who were unable to access supplies of buprenorphine during this period.</p><p>Since this period, the Department has remained in regular contact with all United Kingdom licensed suppliers of buprenorphine and has been working closely with them to monitor their supply position. Based on these conversations, we have been assured that the available supplies are sufficient to meet the usual UK requirements for this drug. The Department continues to monitor this very closely.</p><p>As there have been no long-term shortages of buprenorphine tablets, no such assessment has been undertaken on the impact of this scenario on individuals and substance misuse treatment providers. The Department is aware that since the short-term supply issue affecting buprenorphine, the market price has increased. This increased purchase price is reflected in the reimbursement price paid to pharmacies, to ensure that supplies remain available to patients.</p>
answering member printed Lord O'Shaughnessy more like this
grouped question UIN HL10394 more like this
question first answered
less than 2018-10-15T11:00:26.567Zmore like thismore than 2018-10-15T11:00:26.567Z
answering member
4545
label Biography information for Lord O'Shaughnessy more like this
tabling member
1138
label Biography information for Lord Carlile of Berriew more like this